Hydroxychloroquine Manufacturers in India
India is the dominant producer of hydroxychloroquine because it is a cheap drug used in the treatment of malaria, rheumatoid arthritis and lupus. India had about 6 800,000 malaria cases (3% of the global total), where nearly 8,000 deaths (2% of the global total) are 2018, according to the World Health Organization’s malaria report for 2019. Chlorin phosphate is often used to treat malaria, but hydroxychloroquine, a less toxic variant, is also used in some cases.
Meanwhile, the Ingo has also been working on creating a reserve to meet domestic needs. Both Zydus Cedilla and IPCA Labs are working to meet the requirements of the Ingo.
The IPCA lab has a capacity of 20 metric tons and produces 100 000 000 tablets per month. Ajit Kumar Jain, co-chief executive officer of IPCA Labs, said: “Niro has placed important orders. “We can increase our production capacity by 26 tons per month. We also run our packaging and mark lines at the same time.
Healing Pharma and Pharma companies are integrated into production, which means that they have the necessary raw materials and main feeders.
Although IPCA Labs is subject to U.S. import warnings. The U.S. Food and Drug Administration (FDA) has prevented its sales in the U.S. for violating good manufacturing practices since 2015, and on March 20, the U.S. Food and Drug Administration (FDA) issued an exception allowing the active drug ingredients hydrogen sulfate and hydroxychloroquine produced at its Ratnam plant, as well as hydroxychloroquine sulphate tablets produced in its preparations. The company said the FDA could change the rule as the deficit improves.
IPCA Labs produces hydroxychloroquine at four or five plants in the west of India, while Zydus Cedilla also produces several plants. “The focus is on making sure there are enough drugs available for patients,” says Patel of Zydus Cedilla.